Related Experiment Video
Updated: May 10, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
[Anticonvulsant effect of dicholine succinate on primary generalized epilepsy model in mice]
Abstract:
The anticonvulsant effect of dicholine succinate (DCS), a neuronal insulin sensitizer, has been studied on two models of primary generalized epilepsy induced by corazole and maximal electroshock (ME) in mice. It has been found that DCS administered intraperitoneally for 7 days in a dose of 10 mg/kg produces a significant anticonvulsant effect on the model of corazole-induced seizures. The drug increases the latency of corazole-induced seizures, changes the character of seizures, and increases lifespan of animals, while not protecting against loss. At the same time, DCS does not exhibit any effect on ME-induced seizures.
Insights
Dicholine succinate (DCS), a neuronal insulin sensitizer, shows anticonvulsant effects in a mouse model of corazole-induced epilepsy. However, DCS did not demonstrate efficacy against maximal electroshock-induced seizures in the study.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Epilepsy is a neurological disorder characterized by recurrent seizures.
- Developing novel anticonvulsant therapies remains a critical area of research.
- Neuronal insulin sensitizers are being explored for their potential therapeutic effects.
Purpose of the Study:
- To investigate the anticonvulsant properties of dicholine succinate (DCS).
- To evaluate DCS efficacy in two distinct models of primary generalized epilepsy.
- To assess the impact of DCS on seizure latency, seizure characteristics, and survival rates.
Main Methods:
- The study utilized two established epilepsy models in mice: corazole-induced seizures and maximal electroshock (ME)-induced seizures.
- Dicholine succinate (DCS) was administered intraperitoneally at a dose of 10 mg/kg for seven consecutive days.
- Anticonvulsant effects were assessed by measuring seizure latency, seizure severity, and animal survival.
Main Results:
- Dicholine succinate (DCS) demonstrated a significant anticonvulsant effect in the corazole-induced seizure model.
- DCS increased seizure latency and altered seizure characteristics in corazole-treated mice, improving survival.
- No significant anticonvulsant effect of DCS was observed in the maximal electroshock (ME)-induced seizure model.
Conclusions:
- Dicholine succinate (DCS) exhibits specific anticonvulsant activity against corazole-induced seizures in mice.
- The findings suggest DCS may have potential as a therapeutic agent for certain types of epilepsy.
- Further research is warranted to elucidate the mechanisms of action and therapeutic potential of DCS in epilepsy.
More Related Videos
Related Concept Videos
Depolarizing Blockers: Pharmocokinetics
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

